Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox versus placebo in low/intermediate-1 risk myelodysplastic syndromes with transfusional iron overload
2009-012418-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS), transfusional hemosiderosis and hemosiderosis comparing Deferasirox with Placebo (2 arms). Primary endpoint: Event-free survival. Started Nov 2009; status: completed.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)transfusional hemosiderosishemosiderosis
Beyond the preview
Go deeper on 2009-012418-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012418-38.